52a10f37-ee39-4805-908e-b9e35fa983e9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 51.1129363449692
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- MYOGENESIS+0.470
- ANGIOGENESIS+0.400
- HEDGEHOG_SIGNALING+0.380
- INTERFERON_ALPHA_RESPONSE+0.350
- COAGULATION+0.330
- TGF_BETA_SIGNALING+0.310
- APICAL_JUNCTION+0.280
- APICAL_SURFACE+0.240
- KRAS_SIGNALING_UP+0.190
Top 10 suppressed
- MYC_TARGETS_V2-0.600
- E2F_TARGETS-0.530
- MYC_TARGETS_V1-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.420
- G2M_CHECKPOINT-0.410
- MTORC1_SIGNALING-0.350
- OXIDATIVE_PHOSPHORYLATION-0.330
- DNA_REPAIR-0.300
- FATTY_ACID_METABOLISM-0.270
- PI3K_AKT_MTOR_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 40b98f15-43cb-426b-880c-951a4b28c3e2 | — | — | 0.895 |
| 2 | 4f709f4b-3140-47be-b55a-7713062545e9 | — | — | 0.889 |
| 3 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.880 |
| 4 | TCGA-CN-6016-01A-11R-1686-07 | — | — | 0.877 |
| 5 | TCGA-97-8547-01A-11R-2403-07 | — | cohortA1 | 0.865 |
| 6 | 59f108c6-677f-4cf2-89fd-6bd15133dd6f | — | — | 0.864 |
| 7 | SRR975557 | — | — | 0.864 |
| 8 | TCGA-CV-5444-01A-02R-1514-07 | — | — | 0.863 |
| 9 | 1ab4a652-7fde-4128-ade4-0a1c56eede64 | — | — | 0.862 |
| 10 | TCGA-69-7763-01A-11R-2170-07 | — | cohortA2 | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| MYOGENESIS | 0.470 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| HYPOXIA | 0.180 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.120 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |